Literature DB >> 10204569

Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity.

R L Cotter1, W J Burke, V S Thomas, J F Potter, J Zheng, H E Gendelman.   

Abstract

Since the first description of Alzheimer's disease (AD) in 1907, significant progress was made into understanding disease pathophysiology. The enormous effort in AD research has translated into the discovery of genetic linkages for disease, into elucidating the structure and function of the etiologic beta-amyloid protein, and into unraveling the seemingly complex neuroimmunological cascade that affects neuronal dysfunction. Although effective therapies do not currently exist, many are being developed. We propose that the neuropathogenesis of AD, in measure, revolves around the immunological activation of glial cells, which in turn leads to alterations in inflammatory neurotoxin production, and ultimately to neuronal injury and death. Elucidating the mechanisms involved in such glial cell immune activation should provide valuable insights into understanding the disease process and in providing effective therapeutics to prevent and/or retard the devastating neurodegeneration that afflicts so many of our elderly.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204569     DOI: 10.1002/jlb.65.4.416

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  16 in total

1.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 2.  Toll-like receptors are key players in neurodegeneration.

Authors:  Daniela S Arroyo; Javier A Soria; Emilia A Gaviglio; Maria C Rodriguez-Galan; Pablo Iribarren
Journal:  Int Immunopharmacol       Date:  2011-05-25       Impact factor: 4.932

Review 3.  Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease.

Authors:  Pablo Iribarren; Ye Zhou; Jinyue Hu; Yingying Le; Ji Ming Wang
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Pathogenesis of Human Immunodeficiency Virus Type-1 (HIV-1)-Associated Dementia: Role of Voltage-Gated Potassium Channels.

Authors:  James P Keblesh; Benjamin C Reiner; Jianuo Liu; Huangui Xiong
Journal:  Retrovirology (Auckl)       Date:  2008

5.  HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels.

Authors:  Enrique Gonzalez; Brad H Rovin; Luisa Sen; Glen Cooke; Rahul Dhanda; Srinivas Mummidi; Hemant Kulkarni; Michael J Bamshad; Vanessa Telles; Stephanie A Anderson; Elizabeth A Walter; Kevin T Stephan; Michael Deucher; Andrea Mangano; Rosa Bologna; Seema S Ahuja; Matthew J Dolan; Sunil K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

Review 6.  HIV in the CNS: pathogenic relationships to systemic HIV disease and other CNS diseases.

Authors:  D M Rausch; M R Davis
Journal:  J Neurovirol       Date:  2001-04       Impact factor: 2.643

Review 7.  Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases.

Authors:  I Kadiu; J G Glanzer; J Kipnis; H E Gendelman; M P Thomas
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

8.  In vivo indomethacin treatment causes microglial activation in adult mice.

Authors:  M M Prechel; C Ding; R L Washington; M S Kolodziej; M R Young
Journal:  Neurochem Res       Date:  2000-03       Impact factor: 3.996

Review 9.  NanoART, neuroAIDS and CNS drug delivery.

Authors:  Ari Nowacek; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

Review 10.  Voltage-gated potassium channel modulation of neurotoxic activity in human immunodeficiency virus type-1(HIV-1)-infected macrophages.

Authors:  Elizabeth Irvine; James Keblesh; Jianuo Liu; Huangui Xiong
Journal:  J Neuroimmune Pharmacol       Date:  2007-03-31       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.